Elasmogen Ltd, the Aberdeen-based biologics drug discovery company and Almac Discovery, a pharmaceutical company focused on identifying and developing innovative therapeutics for the treatment of cancer, have entered into an agreement to co-develop Elasmogen’s soloMER technology for the treatment of solid tumors. Elasmogen and Almac will jointly manage the research and development activities aimed at developing a drug candidate to an undisclosed target. Both parties will share costs, with Alm...